news
Sanofi and GSK start Phase II study of their COVID-19 vaccine candidate
The dose finding study will assess the safety, reactogenicity and immunogenicity of the companies’ investigational COVID-19 vaccine in 720 participants.
List view / Grid view
Sanofi Pasteur
Filter the results
news
UK secures total of 357 million doses of various COVID-19 vaccines
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
news
EC approves new meningitis vaccine
MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
news
200 million doses of COVID-19 vaccine to be made available for COVAX
Sanofi and GSK have agreed to support the COVID-19 vaccine (COVAX) Facility with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine.
news
Sanofi and GSK initiate Phase I/II trial of COVID-19 vaccine candidate
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.
news
H7N9 influenza vaccine clinical trials begin
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States...
news
Sanofi Pasteur and MSD end joint vaccines business in Europe
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Sanofi and its vaccines business unit Sanofi Pasteur will end their vaccine joint-venture with MSD (known as Merck in the US and Canada) - SPMSD...
news
BARDA grants Sanofi $43.2 million for Zika vaccine development
27 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In July, Sanofi revealed the development agreement with the Walter Reed Army Institute of Research on the co-development of a Zika vaccine candidate...
news
Sanofi sends half a million dengue vaccines to high risk Brazilians
15 August 2016 | By Sanofi
Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…
news
World’s first public dengue immunisation programme starts
5 April 2016 | By Victoria White
Dengvaxia vaccinations of one million students from 6,000 public schools in the Philippines are to begin this year...
news
Sanofi Pasteur and MSD to end joint vaccines operations in Europe
8 March 2016 | By Victoria White
Upon concluding their joint venture, Sanofi Pasteur and MSD plan to integrate their respective European vaccine businesses into their operations...
article
Zika Virus: a public emergency of international concern
4 February 2016 | By Victoria White, European Pharmaceutical Review
The Zika virus has taken hold in South America. Its possible link to microcephaly in newborn babies and neurological conditions has led the World Health Organization to declare a Public Health Emergency of International Concern. Here we discuss the virus, countermeasures and the race for a vaccine.
news
Sanofi Pasteur’s Dengvaxia approved in Brazil
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants in clinical trials and prevent 8 out of 10 hospitalisations due to dengue and up to 93% of severe dengue cases...
news
Sanofi Pasteur’s Dengvaxia approved in the Philippines
Dengvaxia is the first vaccine licensed for the prevention of dengue in the world...
news
First shipment of ShanIPV to be distributed in India
1 December 2015 | By Victoria White
These first vaccine doses will be available to implement one dose of IPV for all infants in the country...